Mark Biwojno
Contributor since: 2015
Company: 8K EXPERTS
Latest Articles
Fulgent Genetics: Can Ming Hsieh Do It Again?
Mon, Mar. 19 FLGT
Cytokinetics: Separating The Wheat From The Chaff
Oct. 26, 2017 CYTK38 Comments
Portage Biotech: An Apparent Large Discount To Liquidation Value
Editors' PickOct. 6, 2017 PTGEF63 Comments
Profiting From Rising Interest Rates: The Case For Long HEDJ Between 2017-2020
Jan. 19, 2017 HEDJ2 Comments
A Response To $15 Minimum Wage Hurts Us All
Jun. 21, 2016 6 Comments
Does U.S. Physical Therapy Have A Disruptive Business Model?
Apr. 14, 2016 USPH
RPX Corporation: Is The Party Over For This Patent Troll Killer?
Apr. 5, 2016 RPXC2 Comments
Lipocine: The First To Market Oral Testosterone Pill?
Apr. 1, 2016 LPCN9 Comments
The 'Jobless' Portfolio Foreword Test: Beating The S&P
Nov. 2, 2015 ABM, AMZN, COG10 Comments
Uniqure: Leveraging A €3M Acquisition Into A Nearly $300M Shareholder Gain
Apr. 9, 2015 QURE2 Comments
Facebook: The Poster Child Of 'Jobless' Companies
Mar. 31, 2015 FB35 Comments
Capital Preservation: Actually An Aggressive Strategy
Mar. 25, 2015 XHB, ITB, REZ2 Comments
Why A Fed Hike Could Help HEDJ Investors
Editors' PickMar. 19, 2015 HEDJ25 Comments